Cargando…

Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis

BACKGROUND: Prevalence of hepatitis C virus (HCV) infection among people who inject drugs (PWID) in Iran is high. Since 2005, the Iranian government has implemented a harm reduction program to control HCV. We aimed to describe the prevalence of HCV antibody (Ab) in Iranian PWID before and after the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajabi, Abdolhalim, Sharafi, Heidar, Alavian, Seyed Moayed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825164/ https://www.ncbi.nlm.nih.gov/pubmed/33482831 http://dx.doi.org/10.1186/s12954-020-00441-9

Ejemplares similares

Harm reduction during the COVID-19 outbreak in Iran
por: Karimi-Sari, Hamidreza, et al.
Publicado: (2020)

Appropriate Genotyping of Hepatitis B Virus in Iran
por: Jazayeri, Seyed Mohammad, et al.
Publicado: (2015)

Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers
por: Rashti, Roya, et al.
Publicado: (2020)

IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients
por: Sharafi, Heidar, et al.
Publicado: (2011)

Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?
por: Sharafi, Heidar, et al.
Publicado: (2018)

Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

How Can We Make Decision for Patients With Chronic Hepatitis B According to Hepatitis B Virus (HBV) DNA Level?
por: Keshvari, Maryam, et al.
Publicado: (2014)

What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?
por: Keshvari, Maryam, et al.
Publicado: (2014)

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
por: Sharafi, Heidar, et al.
Publicado: (2015)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

695. Infective endocarditis in people who inject drugs (PWID) at UK Medical Center
por: Cari, Evelyn Villacorta, et al.
Publicado: (2020)

Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID) infections in persons who inject drugs
por: Lim, Jacqueline, et al.
Publicado: (2022)

225. Dalbavancin Usage in Patients Who Inject Drugs (PWID)
por: Patel, Kaya, et al.
Publicado: (2023)

Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
por: Moradi, Ghobad, et al.
Publicado: (2021)

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
por: Tasavon Gholamhoseini, Mohammad, et al.
Publicado: (2022)

People who inject drugs (PWID) and HIV/aids cases in Mexico City: 1987–2015
por: Romero Mendoza, Martha, et al.
Publicado: (2019)

1050. Hepatitis C Infection amongst People who Inject Drugs (PWID): Injection Practices and Risk Factors
por: Sankar, Nityasri, et al.
Publicado: (2020)

Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives
por: May, Tom, et al.
Publicado: (2022)

Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India
por: Solomon, Sunil S., et al.
Publicado: (2016)

The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study
por: Sharafi, Heidar, et al.
Publicado: (2014)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

Injection cessation and relapse to injection and the associated factors among people who inject drugs in Iran: The Rostam study
por: Mehmandoost, Soheil, et al.
Publicado: (2023)

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C
por: Pouryasin, Mohammad, et al.
Publicado: (2016)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
por: Sharafi, Heidar, et al.
Publicado: (2020)

Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis
por: Aalaei-Andabili, Seyed Hossein, et al.
Publicado: (2014)

Interferon Alpha-2b Therapy in Chronic Hepatitis Delta
por: Keshvari, Maryam, et al.
Publicado: (2014)

1409. Infectious Complications in People Who Inject Drugs (PWID): A Retrospective Review and Recommendations for Improved Care
por: Martin, Elena K, et al.
Publicado: (2022)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

Measures of harm reduction service provision for people who inject drugs
por: O’Keefe, Daniel, et al.
Publicado: (2019)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis
por: Ghaderi-Zefrehi, Hossein, et al.
Publicado: (2016)

1021. Repeat Infective Endocarditis (rIE) in Persons Who Inject Drugs (PWID)
por: Huang, Glen, et al.
Publicado: (2018)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

HIV incidence among people who inject drugs (PWID) in Ukraine: results from a clustered randomized trial
por: Booth, Robert E., et al.
Publicado: (2016)

Establishing trust in HIV/HCV research among people who inject drugs (PWID): Insights from empirical research
por: Abadie, Roberto, et al.
Publicado: (2018)

1024. First Episode Infective Endocarditis in Persons Who Inject Drugs (PWIDs); A Retrospective Cohort Study
por: Rodger, Laura, et al.
Publicado: (2018)

Reviewing harm reduction for people who inject drugs in Asia: the necessity for growth
por: Stone, Katie Alexandra
Publicado: (2015)

Stigmatization of people who inject drugs (PWID) by pharmacists in Tajikistan: sociocultural context and implications for a pharmacy-based prevention approach
por: Ibragimov, Umedjon, et al.
Publicado: (2017)

1890. Missed Clinical Opportunities to Prevent Infections and Treat Substance Use Disorder (SUD) in People Who Inject Drugs (PWID)
por: Bardossy, Ana C, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9754ea300ee2gbcoqm7a9h3igb